New Mexico Mesothelioma Information | Surviving Mesothelioma

Mesothelioma in New Mexico

While mesothelioma is a problem in all states, the specific incident rate for New Mexico is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in NM, recent NM mesothelioma-related court cases, mesothelioma specialists in NM and potential asbestos hotspots in New Mexico.

New Mexico Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of New Mexico

New Mexico Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

New Mexico Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

New Mexico Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract: DESCRIPTION (provided by applicant): Exposures to airborne asbestos and man-made vitreous fibers (MMVFS) increase the incidence of lung cancer, asbestosis, and mesothelioma. Fibers that deposit in the bronchial and alveolar regions, subsequently translocating to the parenchyma, are thought to be responsible for the development of these diseases. Physico-chernical properties of fibers, including length, diameter, and durability in the lung, are major factors in the etiology of these lung diseases. Because inhalation is the main route of exposure, the deposition pattern in the respiratory tract as a function of fiber dimensions is new information critical to understanding respiratory dosimetry and defining the index of exposure for health protection purposes. Controlled studies of fiber deposition in human volunteers are not available because of ethical concerns. However, total and regional depositions of inhaled fibers have been estimated from postmortem measurement, mathematical modeling, and animal toxicity studies. Increasingly, mathematical deposition models have been used to assess the dosimetry of inhaled MMVFS. However, current lung dosimetric models for fibers in the human respiratory tract are based on theoretical equations, which have not been verified with experimental data. This proposal has three objectives: (1) to develop experimental information on the deposition of fibrous aerosols as a function of fiber diameter and length in realistic human respiratory tract replicas, (2) to verify and improve the prediction of fiber dose estimate in human lungs using both empirical data as well as a computational fluid dynamic technique, and (3) to define,.a size-selective exposure index based on fiber penetration data. Because lung diseases caused by inhaled fibers occur in the bronchial, alveolar, and parachymal regions, a thoracic fraction defined as the fraction of particles penetrating the larynx and reaching the lung must be established and will be defined from experimental data obtained in this study. This research will generate essential information on the dosimetry of inhaled fibers in the human lung, data for an improved mathematical lung deposition model, and a definition of the thoracic fraction of fibers for exposure assessment. Sampling devices based on this size-selection definition can be developed in the future for improved assessment of worker exposure.

Tags: Aerosol, Environmental Exposure, Lung Injury, Occupational Health /safety, Particle, Pulmonary Respiration Air Pollution, Asbestos, Bronchus, Fluidity, Irritation /irritant, Lung Neoplasm, Mathematical Model, Mesothelioma, Occupational Hazard, Pollution Related Respiratory Disorder, Respiratory Airway Clearance, Respiratory Hypersensitivity, Respiratory Toxin, Statistics /biometry Radiation Dosage, Respiratory Airflow Measurement, Transmission Electron Microscopy

  • Followup Grant: 5R01OH003900-03
  • Followup Grant: 5R01OH003900-04
  • Followup Grant: 5R01OH003900-05

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Intervention: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: doxorubicin hydrochloride; Drug: ranpirnase
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

Condition: Mesothelioma
Intervention: Drug: Pemetrexed; Drug: Gemcitabine
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Liposomal doxorubicin; Drug: Cisplatin
More Information

Hospital and Cancer Centers

We do not have any doctors or cancer centers for this state at the moment.

Cases

We do not have any cases for this state at the moment.

Lawyers

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

[contact-form-7 id=”372″ title=”Occupation”]

Get your free copy of
“Surviving Mesothelioma” Today!